Compare Apple Inc (AAPL) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs BridgeBio Pharma Inc — how do they compare? Apple Inc trades at $313.29 (market cap $4.56T), while BridgeBio Pharma Inc trades at $78.11 (market cap $15.26B). The key difference: Apple Inc is far larger — about 298.8× BridgeBio Pharma Inc's market cap, and Apple Inc pays a 0.35% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| AAPL | BBIO | |
|---|---|---|
Market Cap | $4.56T | $15.26B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $79.91 |
52-Week Low | $202.38 | $43.19 |
Enterprise Value | $4.58T | $16.81B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $313.28, up 0.2% on the day, with a bullish technical signal and strong support at $309. Recent earnings beats and a 26.91% net margin in 2025 highlight robust profitability. Revenue grew to $416.16B in 2025, with further growth projected to $451.4B in 2026. Positive news includes leading smartphone shipments and institutional buying, though union-busting allegations and potential Q2 2026 earnings miss pose concerns.
Outlook remains positive with a consensus price target of $329.62, offering ~5% upside. Strengths include high margins, cash flow generation, and AI opportunities via 2.5B device base. Risks involve competitive pressures, regulatory scrutiny from EU fines, and reliance on iPhone sales. Analyst sentiment is bullish (63% buy ratings), but investors should monitor execution against earnings expectations.
BridgeBio Pharma (BBIO) trades at $77.91, up 0.93% on the day, supported by a bullish technical outlook and strong analyst consensus. The stock shows robust revenue growth, with 2025 revenue reaching $502.08M, though it remains unprofitable with a net income margin of -124.41%. Recent positive news includes a $1 billion preferred equity raise and regulatory progress for key drug candidates, fueling investor optimism despite ongoing cash burn from operations.
The investment case hinges on the company's pipeline catalysts and commercial execution, with a consensus price target of $102.75 implying significant upside. However, high cash burn, negative equity, and consistent earnings misses present substantial risks, requiring careful monitoring of upcoming clinical and regulatory milestones for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
